

Outcome Measures: The Role of Objective, Physiologic and Safety Data

Edward M Sellers MD, PhD, FRCPC, FACP
Professor Emeritus, University of Toronto
Vice-President Kendle Early Stage
Kendle International
Toronto, Canada

IMMPACT-XII Rockville, MD

October 1, 2009

Framing the Topic

- Topic definition somewhat arbitrary
 - Physiologic versus non-physiologic??
 - Subjective versus objective
 - Measured by the brain versus a machine
- Measurements that don't relate to the likely reinforcing properties of a drug or behaviors related to taking drug
 - Many physiologic adverse events can be punishing and decrease likelihood of repeated drug taking
 - Many physiologic events can teach as to similarity to known drugs of abuse
- Some physiologic or behavioral adverse events e.g. perceptual change with opioids with kappa or sigma activity suggest different types of abuse



Defining Topic Areas

1. Safety measures

- Human experimental studies
 - Physiologic measures
 - Adverse event reports
- Clinical trials
 - Adverse events reports

2. Pharmacologic effects

- Human experimental studies
- Clinical trials

3. Pharmacokinetics



Analgesic Development

- Historically full agonist opioids
- Varying degrees of mu selectivity and specificity
- Novel receptor systems – prototypic pharmacologic framework won't work very well
- Peripheral and central actions
- Adjunct therapies



Human Experimental Studies

- Single dose cross over with 2-3 dose levels of active drug
- **Some doses will be high doses often near the MTD**
 - Prior exposure in limited number of subjects (i.e., SAD / MAD studies with 6-8 subjects)
 - Margin of safety of the drugs determines the form and intensity of the monitoring
 - The margin of safety often becomes apparent during the study
- Subjects are “healthy” volunteers / drug users, screened for risk factors and often screened for ability to tolerate doses (pre-study “qualification”)
 - Almost 50% will fail medical screening
 - The less stringent the study inclusion/exclusion criteria or the less robust the screening process the greater the risk?
- Comments may not apply necessarily to drug discrimination studies or low dose self administration studies




Standard Safety Monitoring

- Type, frequency and timing matched to PK and risk
- Adverse events
 - Spontaneous
 - Elicited
- Types of monitoring
 - Cardiovascular
 - Respiratory
 - Laboratory
 - Urine drug testing




Varenicline: VAS Liking Bipolar Scale – Liking Disliking

Time Course for VAS Drug Liking – Smokers



Varenicline: Nausea

Nonsmokers




Cardiovascular Monitoring

- Blood pressure and heart rate
 - Observer driven
 - Automatic
 - Electronic data transfer
- Intermittent electrocardiograms
- Cardiac Telemetry –
 - Intermittent
 - Continuous
 - 12-72 h full disclosure



Examples of Cardiac Events on Telemetry

- VPB and APBs
- Bradycardia – HR <40
- Vasovagal events
- Supraventricular tachycardia
- Persistent bigeminy
- Ventricular tachycardia – 4 to 52 beats
- Asystole 30 seconds



Respiratory Monitoring

- Respiratory function
 - Respiratory rate
 - Automatic recording
 - Tidal volume
 - Minute volume
- SaO₂
 - Continuous or intermittent (often part of telemetry)
 - 95%/90%
 - Late onset with CR opioids
- End tidal CO₂
- CO₂ sensitivity
- Arterial blood gases



Clinical Laboratory: During a Study

- Selection based on standard panels or targeted to actual risk?
- Very few really add value – way too many are done
- Boiler plate protocols and legacy traditions
- Regulatory tradition and expectation – measure a lot




Urine Drug Testing

- Not a safety test – is a drug use test
- Qualitative, semi-quantitative, quantitative
- Thresholds and cut offs are arbitrary
- No relationship of positive UDS and clinical effects
- No evidence that any level in the urine alters the pharmacodynamic measures in a human abuse liability study if no evidence of clinical intoxication
- Paradox – study is in drug users but they are meant to have negative UDS!!!
 - Some sponsors may not even want to see the drug that is being given in the study show in the urine eg benzodiazepines




Other Measures

- Motor tracking performance with divided attention task
- Simple and complex reaction time
- Cognitive testing - memory, executive function
- EEG
 - Intermittent or continuous
 - Evoked potential
 - Sensory gating
- Pupillometry
- Lumbar puncture
 - single
 - Multiple
 - cannula
- fMRI
- PET




Pupillometry

Placebo Response



Fentanyl Response



Opioid Pharmacology

- Pupilometry
- Heart rate
- Respiratory rate
- Lacrimation and salivation
- Bowel sounds
- Micturition
- Nausea and vomiting
- Postural steadiness




Stimulant Pharmacology

- Heart rate
- Blood pressure
- Tremor
- Reflexes
- Pupilometry
- Cognitive function,
- reaction time,
- motor tracking, attention (may be improved)




Stimulant-Induced Changes in Vital Signs

Systolic Blood Pressure (mm Hg)



Heart Rate (bpm)



Hours post-dose




Sedating Agents

- Cognitive function,
- reaction time,
- motor tracking,
- attention (impaired)
- Critical flicker fusion
- Ocular pursuit
- Standing steadiness platform
- EEG
 - Evoked potentials
 - Topographic mapping




Impaired Cognition and Subjective Sedation

**Divide Attention Test with Manual Tracking
(Percentage Over Road)**



Subjective "Sedation" (ARCI PCAG)




Pharmacokinetics


- Options
 - Don't do any
 - Sparse PK
 - Full PK
 - PK-PD modelling
- What is the question?
 - Drug got in?
 - Drug concentration relates to effect?
 - Variation in PK relates to variation in effects?
 - Maximum concentrations seen in animals – toxicokinetics limits permitted human exposure?



Assessing Abuse Liability: Methylphenidate Kinetics



PK-PD Relationships?



Safety Data Collection – Meeting the Standard

- Electronic data collection, transfer and management
- 21CFR11 compliant systems
- Live QC
- Study monitoring
- Study audit



Staff Training and Supervision

- MDs, paramedics and RNs
 - All ACLS certified
- Evacuation SOP and drills
- Hospital transfer protocol
- MD present through-out or available within minutes




Clinical Trials

- Doses are “therapeutic” – risk lower
- Vital signs and AE collection at time of visits
- Safety challenge
 - AE clinical terms, coding, interpretation, presentation
 - AEs associated with treatment period and discontinuation period
 - Spontaneous and elicited
 - Fox and the chicken coop – role of independent AE review?
- Other physiologic measures
 - Not needed in most cases
 - Cardiovascular risk



Kendle
Real people. Real results.®

Varenicline: VAS Liking Bipolar Scale – Liking Disliking



Asystole

